血管内取栓改善急性缺血性卒中生存:一项荟萃分析
该荟萃分析纳入2018年美国卒中协会/美国心脏协会指南引用的10项随机临床试验,比较血管内取栓(EVT)与药物治疗对急性缺血性卒中90天死亡率的影响。结果显示EVT显著降低90天死亡风险(15.0% vs 18.7%;RR 0.81;95%CI 0.68-0.98;
要点
- EVT较药物治疗显著降低急性缺血性卒中90天死亡风险。
- EVT与药物治疗的90天颅内出血风险无显著差异。
- 早期和晚期时间窗试验中EVT的生存获益趋势相似。
核心结论
- 对于急性缺血性卒中,EVT较单纯药物治疗显著改善90天生存。
研究设计与样本
- 荟萃分析纳入2018年AHA/ASA指南引用的10项EVT vs 药物治疗随机临床试验,共2313例患者。
临床怎么用
- 对于符合指南推荐的急性缺血性卒中患者,EVT可作为改善90天生存的治疗选择。
局限性
- 纳入试验存在方案异质性,且过早终止的试验可能引入偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Although endovascular thrombectomy (EVT) in acute ischemic stroke is recommended by guidelines to improve functional recovery, thus far there are insufficient data on its association with mortality. OBJECTIVE: To identify guideline-relevant trials of EVT vs medical therapy reporting 90-day mortality and perform a meta-analysis. DATA SOURCES: All randomized clinical trials cited for recommendations on EVT vs medical therapy in the latest 2018 American Stroke Association/American Heart Association guidelines. STUDY SELECTION: Ten American Stroke Association/American Heart Association guideline-relevant randomized clinical trials of EVT vs medical therapy were selected for inclusion. Two EVT trials were excluded owing to infrequent use of EVT. DATA EXTRACTION AND SYNTHESIS: Data were abstracted by 2 independent investigators and double-checked by 4 others. Singular study data were integrated using the Cochran-Mantel-Haenszel method and a random-effects model to compute summary statistics of risk ratios (RR) with 95% CIs. MAIN OUTCOMES AND MEASURES: Risk of 90-day mortality and 90-day intracranial hemorrhage was analyzed; sensitivity analyses were performed in early-window EVT trials (which included patients from the onset of symptoms onward) vs late-window EVT trials (which included patients from 6 hours after onset of symptoms onward). RESULTS: In 10 trials with 2313 patients, EVT significantly reduced the risk for 90-day mortality by 3.7% compared with medical therapy (15.0% vs 18.7%; RR, 0.81; 95% CI, 0.68-0.98; P = .03). Trends were similar in early-window (RR, 0.83; 95% CI, 0.67-1.01; P = .06) and late-window trials only (RR, 0.76; 95% CI, 0.41-1.40; P = .38). There was no difference in the risk for intracranial hemorrhage in EVT vs medical therapy (4.2% vs 4.0%; RR, 1.11; 95% CI, 0.71-1.72; P = .65). Limitations of the studies include trial protocol heterogeneity and bias originating from prematurely terminated trials. CONCLUSIONS AND RELEVANCE: This meta-analysis of all evidence on EVT cited in the 2018 American Stroke Association/American Heart Association guidelines shows significant benefits for survival during the first 90 days after acute ischemic stroke compared with medical therapy alone.
引用
- Lin Y, Schulze V, Brockmeyer M, et al. Endovascular Thrombectomy as a Means to Improve Survival in Acute Ischemic Stroke: A Meta-analysis. JAMA Neurol. 2019. PMID: 30958530. doi:10.1001/jamaneurol.2019.0525
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。